A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus

NCT04050553 · Completed

Last updated 2026-05-28

This clinical trial is testing the effects of tirzepatide on people with type 2 diabetes to see how it influences glucagon levels during controlled low blood sugar.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 42 people

Who can join Ages 18–70 · all sexes

Timeline Started 2020-02 · est. completion 2022-01

Where 1 site · Austria

What this study is testing ClinicalTrials.gov NCT04050553 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn more about how tirzepatide affects the body's response to low blood sugar (hypoglycemia). The study is open to participants with type 2 diabetes. It will last about 42 weeks for each participant.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change in Mean Glucagon Concentration During Induced Hypoglycemia From Target Plasma Glucose (PG) Concentration of 100 Milligrams Per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2, Hypoglycemia
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04050553 ↗